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Abstract
Background: Spatio-temporal control of extracellular signal-regulated kinase (ERK) activity, a 
critical determinant of the cell's response to growth factors, requires timely dephosphorylation of 
its regulatory tyrosine and/or threonine residue by MAPK phosphatases. W e studied the 
physiological role of kinase interaction motif (KIM)-containing protein tyrosine phosphatases 
(PTPs) in the control of EGF- and NGF-induced ERK activity in neuroendocrine PCl2 cells.
Results: W e found a single KIM-containing PTP to be endogenously expressed in rat PCl2 cells: 
the transmembrane PTPRR isoform termed PCPTPl. Protein knock-down of PCPTPl, or fourfold 
overexpression of its mouse orthologue, PTPBR7, left EGF- and NGF-induced ERKl/2 activity in 
PCl2 cells unaltered. Ectopic expression of cytosolic PTPRR isoforms, however, resulted in 
reduced EGF-induced ERKl/2 activity, an effect that was dependent on the phosphatase activity and 
the KIM-domain of these PTPs.
Conclusion: The finding that robust changes in tyrosine-specific MAPK phosphatase expression 
levels have minor effects on temporal ERKl/2 activity control in PCl2 cells suggests that dual­
specificity MAPK phosphatases may act as major regulators of growth factor-induced ERKl/2 
signaling in these cells.
Background
One of the best-studied cellular signaling relays is the 
mitogen-activated protein kinase (MAPK) signaling cas­
cade, the central mechanism by which growth factors steer 
cellular key decisions such as proliferation and differenti­
ation [1]. It has become clear that it is not just the ampli­
tude but also the spatio-temporal distribution of the 
MAPK activity within the cell that determines the final 
outcome of this signaling relay. For example, in the rat 
PC12 phaeochromocytoma cell line seminal studies have 
shown that epidermal growth factor (EGF)-induced pro­
liferation relies on a transient activation of the extracellu­
lar signal-regulated kinases 1 and 2 (ERK1/2) in the 
cytosol, whereas nerve growth factor (NGF)-induced dif­
ferentiation requires a sustained ERK1/2 activation and 
translocation to the nucleus [2,3]. Thus, not only signal­
ing molecules that activate these ubiquitous MAPKs but 
also the ones that inactivate and/or localize them are 
important for determining signaling specificity. ERK acti­
vation requires the phosphorylation of two closely spaced 
regulatory tyrosine and threonine residues by the dual 
specificity MAP kinase kinases MEK1/2 [4]. Concomi-
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tantly, ERK inactivation involves dephosphorylation of 
these residues by MAPK phosphatases. Although the EGF 
and NGF specific pathways that lead to ERK activation 
have been mapped in detail in PC12 cells [3], the contri­
bution of MAPK phosphatases in this model system has 
received little attention.
The dephosphorylation of ERK1/2 regulatory tyrosine and 
threonine residues can be achieved by three different 
phosphatase types: protein serine/threonine phos­
phatases, dual specificity (serine/threonine/tyrosine) 
phosphatases (MKPs/DUSPs) and classical phosphotyro- 
sine-specific protein tyrosine phosphatases (PTPs) [5]. 
The latter two types have gained considerable interest 
because they contain a so-called kinase interaction motif 
(KIM) that is also present in the upstream MAPK kinases
MEK1/2. The KIM-domain mediates the interaction and 
in part determines binding specificity towards the differ­
ent MAPKs [6-8]. Importantly, this interaction can be reg­
ulated via cAMP because PKA-mediated phosphorylation 
of a serine residue within the KIM-domain abolishes 
binding and dephosphorylation of MAPKs [9,10].
Mammals contain three classical PTP families that may 
regulate ERK activity by KIM-dependent binding and 
dephosphorylation: HePTP/LC-PTP, STEP and PTPRR 
(Fig. 1A). The haematopoietic HePTP/LC-PTP was indeed 
shown, through gene targeting studies, to be a physiolog­
ical regulator of ERK in lymphocytes [11] and the striatal- 
enriched phosphatase (STEP) enzyme family was found 
to regulate ERK activity in primary neuronal cultures [12]. 
For PTPRR isoforms current data mainly reflect overex­
Figure 1
Tyrosine-specific M APK phosphatases expressed in PC12 cells. A) Schematic diagrams of STEP (STEP6I, STEP46), 
HePTP and PTPRR (PTPBR7, PTP-SL, PTPPBSy-42, PTPPBSy-37) protein isoforms. Mouse isoform nomenclature is given on 
the right. Signal peptides (SP), proline-rich and PEST domains (PP), transmembrane segments (TM), kinase-interacting motifs 
(KIM), hydrophobic regions (HR) and catalytic phosphotyrosine phosphatase domains (PTP) are indicated. B) Assessment of 
KIM-containing, tyrosine-specific PTP expression by RT-PCR. Rat protein nomenclature is indicated on the left, aligned with 
the diagrams of the mouse orthologs depicted in panel A). STEP and HePTP transcripts, as detected by RT-PCR (+) in mouse 
cerebrum (CRB) and spleen (SPL) RNA, respectively, are not found in PCI2 cells. For rat PTPRR proteins (PCPTPI, PCPTPI- 
Ce, PTPPBSy) isoform-specific primer sets were used on rat cerebellum (CBL) and PCI2 total RNA. Samples lacking RT 
enzyme (-) and appropriate plasmids (p) served as negative and positive controls, respectively. A  P-actin specific RT-PCR 
served as a positive control for the reverse transcriptase reactions.
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pression studies in non-neuronal cells [6,9,13]. Given that 
rat PTPRR receptor-type isoform (PCPTP1) mRNA levels 
in PC12 cells are increased nine-fold within 8 h following 
NGF treatment [14], a role in neuronal differentiation 
induced by sustained ERK activity may be expected.
In the current study we assessed the contribution of the 
KIM-domain-containing classical PTPs to the regulation 
of ERK activity in rat PC12 cells. HePTP and STEP mRNAs 
were not detectable in PC12 cells. For the PTPRR gene a 
single transcript type, encoding the transmembrane iso­
form PCPTP1, was encountered. We exploited retroviral 
transduction to increase or decrease PTPRR protein levels 
and monitored growth factor-induced ERK activation 
using phosphospecific antibodies. Our results demon­
strate that KIM-domain-containing tyrosine-specific PTPs 
are dispensable for proper ERK-dependent signaling in 
PC12 cells and put forward the dual-specificity MAPK 
phosphatases as the physiological regulators of ERK activ­
ity in these cells.
Results
A single classical KIM-containing PTP is expressed in PC12 
cells
To determine which of the three KIM-containing phos- 
photyrosine-specific PTPs are endogenously expressed in 
rat PC12 cells, an RT-PCR analysis on total RNA was per­
formed. Expected amplicons for STEP and HePTP were 
obtained from mouse cerebrum and mouse spleen RNA, 
respectively, but STEP and HePTP messengers remained 
undetectable in PC12 material (Fig. 1B), in concordance 
with earlier reports [15,16]. For the rat PTPRR gene two 
different transcripts, encoding PCPTP1 and PCPTP1-Ce, 
respectively, have been reported [17,18]. PCPTP1 mRNA 
is present in PC12 cells [14,17,19] but PCPTP1-Ce tran­
scripts remain undetectable in PC12 RNA, although the 
amplification product is readily obtained using rat cere­
bellum RNA (Fig. 1B). In mouse the PTPRR-encoding 
gene generates a third transcript isoform which encodes 
two additional protein isoforms (PTPPBSy-42 and 
PTPPBSy-37) through the use of alternative translation 
start sites [20]. To be able to probe for the presence of 
putative rat PTPPBSy variants, we searched in public data­
bases for the rat PTPRR genomic region displaying very 
high homology to mouse PTPPBSy transcript-specific 
sequences and designed primers for use in RT-PCR assays. 
Indeed, the predicted PTPPBSy-type fragment was ampli­
fied from rat cerebellum RNA, while mouse PTPPBSy 
cDNA served as positive control, but no signal was 
obtained using PC12 material (Fig. 1B). Thus, in rat PC12 
cells only the largest PTPRR transcript, that encodes the 
receptor-type isoform PCPTP1, is expressed.
We next investigated PTPRR isoform expression in PC12 
cells at the protein level. Both Western blot analysis of
PC12 cell lysates and immunoprecipitation experiments 
revealed multiple immunoreactive bands (e.g. Fig. 2A and 
data not shown) that compare well to patterns obtained 
with expression constructs for rat PCPTP1 [17]. Proteins 
of around 72 and 65 kDa in size are detected that repre­
sent endogenous rat PCPTP1 and a post-translationally 
modified variant, respectively, as is the case for the mouse 
ortholog PTPBR7 [20]. These data are in line with PTPRR 
isoform PCPTP1 to be the only detectable KIM-containing 
phosphotyrosine-specific phosphatase in PC12 cells.
RNAi-mediated knock-down o f  PCPTP1
To assess whether dephosphorylation by PCPTP1 is of rel­
evance for the regulation of EGF- and NGF-induced ERK 
signaling in PC 12 cells, we aimed at silencing PCPTP1 
expression via RNA interference. Different siRNA 
sequences were tested through viral transduction with 
pSUPER-Retro [21] and the one targeted to nucleotides 
2380-2398 of PCPTP1 resulted in an almost complete 
ablation of PCPTP1 protein levels (Fig. 2A). To enable 
exclusion of off-target effects in these cells, knockdown 
was also rescued by introduction of a retroviral expression 
vector encoding PTPBR7, the mouse ortholog of PCPTP1. 
Effects on ERK activity following EGF or NGF administra­
tion to serum-starved PC12 cells were monitored over 
time by immunoblot analysis of cell lysates using phos- 
phospecific ERK1/2 antibodies. Reprobing the same 
immunoblot with antiserum directed against total ERK1 
enabled us to correct for loading differences between sam­
ples and to express ERK1/2 activity as relative phosphor­
ylation units. EGF administration to mock-transduced 
PC12 cells resulted in a very rapid but transient ERK1/2 
activation that peaks within the first 5 min (Fig. 2B, upper 
panels). Upon NGF treatment, ERK1/2 biphosphoryla­
tion is maximal after some 10 min and then gradually 
decreases, with sustained ERK1/2 activity still being 
detectable after 48 h (Fig. 2B, lower panels) [22]. Reason­
ing that possible effects of the altered PCPTP1 levels 
would be most noticeable at time points with maximal 
ERK1/2 activation, we compared relative phospho-ERK1/
2 levels in the transduced cells at 2 and 5 min after EGF 
addition (Fig. 2C) or at 10, 20, 30 and 60 min following 
NGF administration (data not shown). Depletion of 
PCPTP1, however, did not result in significant alteration 
of the response to EGF or NGF administration. Also the 
use of very low EGF concentrations, to ensure that ERK1/
2 is not maximally phosphorylated and PCPTP1 knock­
down may allow further increase of ERK1/2 activity, did 
not reveal a significant difference in ERK 1/2 activation 
between mock transduced and PCPTP1 knockdown cells 
(Fig. 2D).
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Figure2
ERK a c tiv ity  p ro file  is n o t affected by PCPTP1 dep le tion . A) RNAi-mediated knockdown of endogenous PCPTP1 in 
PCI2 cells. PCI2 cells stably expressing siRNA targeted to  nucleotides 2380-2398 in PCPTPI cDNA (pSR-2380) were gener­
ated via retroviral transduction. Empty vector (pSR) was used as control and PCPTPI knockdown was rescued by transduction 
of pSR-2380-containing cells with a retroviral expression construct for the mouse ortholog PTPBR7. Equal amounts of protein 
from the resulting stable cell pools were subjected to immunoprecipitation using a-SL antiserum and captured proteins were 
analyzed on Western blots using monoclonal antibody 6A6. B) Transient and sustained ERKI/2 signaling in wild type PCI2 
cells. After overnight serum deprivation, cells were stimulated with I00 ng/ml EGF (upper panels) or 50 ng/ml NGF (lower 
panels) for the indicated time points. Cell lysates were subjected to  Western blot analysis and phospho-ERKI/2 signals (pERKI, 
pERK2) were detected using a chemiluminescence imaging system. The same blot was reprobed with total ERKI antibody to 
correct for loading differences. C) Transient ERK activity is not affected in PCPTPI knockdown cells. Serum-starved cells were 
stimulated with I0 ng/ml EGF for 2 o r 5 min, respectively, and harvested. Relative phospho-ERKI/2 levels in the protein 
lysates, determined as above, are presented as mean values ± SEM from three independent experiments. D) PCPTPI knock­
down in PCI2 cells does not significantly alter ERK activity at reduced levels of EGF. Serum starved cells were stimulated with 
0.075 ng/ml EGF for the indicated time points and relative phospho-ERKI/2 levels were determined as before. Results are 
mean values ± SEM (n = 4).
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Effects o f  PTPRR overexpression on transient and  
sustained ERK activity
As an alternative way to assess the relevance of PTPRR 
activity for the regulation of ERK signaling, we generated 
pools of PC12 cells that stably expressed mouse PTPRR 
isoforms by means of retroviral transduction. Lysates of 
the resulting cell lines were first analyzed on Western blots 
to determine PTPRR expression levels (Fig. 3A). Transduc­
tion with mouse PTPBR7-encoding viruses resulted in 
immunoreactive bands that superimposed on those of 
endogenous PCPTP1, confirming the previous annotation 
of these signals. Ectopic expression of mouse PTPPBSy 
transcripts resulted in two additional immunoreactive 
bands which represent PTPPBSy-42 and PTPPBSy-37 [20]. 
Cells transduced with a construct encoding PTP-SL, the 
mouse ortholog of PCPTP1-Ce, failed to display apprecia­
ble levels of expression (not shown) and are therefore not 
included in this study. Quantitation revealed that PTPBR7 
expression exceeds three-fold the endogenous PCPTP1 
level, whereas PTPPBSy expressing cells show PTPRR lev­
els that are some seventeen-fold higher than in non-trans- 
duced controls (Fig. 3B). Analysis of the subcellular 
distribution revealed that endogenous PCPTP1 displayed 
a weak vesicle-type of staining in PC12 cells, and only lim­
ited cell membrane localization (Fig 3C, left panel). In 
line with previous data [20,23,24], its mouse ortholog 
PTPBR7 was detected at the cell membrane, on vesicular 
structures and at the Golgi apparatus (Fig. 3C, middle 
panel). Mouse PTPPBSy isoforms are cytosolic proteins 
that are excluded from the nucleus, while endogenous 
PCPTP1 adds a speckled pattern (Fig. 3C, right panel).
Effects of PTPBR7 and PTPPBSy expression on ERK1/2 
activity profiles in the transduced cells were again deter­
mined through phospho-ERK1/2 immunoblots (Fig. 4A). 
Mean values for six independent experiments were plotted 
(Fig. 4B,C) and identical results were obtained using inde­
pendently derived PC12 stably transduced cell pools. 
Ectopic expression of PTPBR7 was found to have no effect 
on EGF-induced transient and NGF-induced sustained 
ERK1/2 activity. At 5 min following EGF addition the 
PTPBR7 expressing cells display a small reduction in 
ERK1/2 activity, but this does not reach significance. Like­
wise, at 2 min following EGF administration and at 10, 
20, 30 or 60 min after NGF treatment the phospho-ERK1/
2 levels in the various cell pools expressing PTPPBSy are 
indifferent from those in mock-transduced cells. On the 
contrary, PTPPBSy expressing cells show a significant 
reduction in ERK1/2 activity levels 5 min after EGF 
administration (p < 0.008; Fig. 4B). Separate analyses of 
the ERK1 and ERK2 activity levels provided essentially the 
same results (data not shown). Thus, boosting PTPRR 
activity in the cytosol 17-fold results in a significant ~25% 
reduction of ERK1/2 activity during the later phase of the 
transient response to EGF.
Figure 3
Expression o f PTPRR isoform s in PC 12 cells. A) PCI2 
cells were retrovirally transduced with expression constructs 
for mouse PTPRR isoforms, o r mock-transduced. Equal 
amounts of cell lysates were subjected to  I0% SDS-PAGE 
and immunoblotting. Rat PCPTPI, mouse PTPBR7 and 
mouse PTPPBSy (indicated on the left) were detected using 
6A6 antibody. Molecular size markers are indicated on the 
right. The arrow indicates a cross-reactive ~50 kDa back­
ground band. B) Quantitative representation of PTPRR 
expression levels as determined in A. PTPRR levels were 
corrected for loading differences using monoclonal a-tubulin 
antibody E7 immunostaining (not shown) as a control. 
Results are the mean values ± SEM of four individual pools of 
cells. C) Subcellular localization of stably expressed PTPRR 
protein isoforms in the transduced PCI2 cells as determined 
by fluorescence microscopy using polyclonal a-SL antibody. 
Bar indicates I0 |im.
PTPRR effects on ERK activity involve KIM-mediated 
interactions
The binding of KIM-domain-containing phosphatases to 
their MAPK targets can be abrogated by the cAMP-depend­
ent protein kinase PKA, through phosphorylation of a 
specific serine residue within the KIM-domain [9,10,12]. 
Intriguingly, current models on transient versus sustained 
ERK activation in PC12 cells incorporate an NGF-induced 
PKA-mediated signaling pathway [22]. To investigate 
whether this mechanism kept PTPRR isoforms from regu­
lating ERK phosphorylation levels in PC12 cells, we inves­
tigated the phosphorylation status of the KIM domain 
serine residue in immunoprecipitated PTPRR proteins
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Figure 4
PTPRR e ffect on g ro w th  facto r-induced ERK signal­
ing. A) PCI2 cells stably expressing PTPPBSy show reduced 
transient ERKI/2 activity. Serum-starved pools of mock- 
transduced, PTPBR7 expressing or PTPPBSy expressing cells 
were treated with I00 ng/ml EGF for 2 or 5 min before being 
lysed. Proteins were size-separated and immunoblotted. 
Representative images of phospho-ERKI/2 (upper panel) and 
total ERKI (lower panel) immunoreactivity are depicted. B) 
Reduced transient ERK activity in PTPPBSy expressing cells. 
Quantitative representation of relative phospho-ERKI/2 lev­
els in cells stimulated with EGF for two or five minutes. 
Results are presented as mean values ± SEM from six inde­
pendent experiments (Student's t-test, *p < 0.008). C) 
Increased PTPRR levels have no effect on NGF-induced 
ERKI/2 activity. Serum starved PCI2 cell pools stably 
expressing PTPBR7 or PTPPBSy were stimulated with 50 ng/ 
ml NGF for the indicated time points (in min). Cells were 
then lysed and phospho-ERKI/2 were analysed on Western 
blots as in panels A-B. Results are the mean ± SEM of three 
independent experiments.
using an antibody directed against phosphorylated PKA 
substrates. Administration of the PKA activator forskolin 
was used to determine maximum levels of KIM-domain 
phosphorylation [12]. Phosphorylation levels of endog­
enous PCPTP1 in PC12 cells were, unfortunately, below 
detection level (data not shown). In PTPPBSy-expressing 
PC12 cells about half of this phosphatase appeared phos- 
phorylated following overnight serum starvation, and 
EGF or NGF administration even led to a significant 
decrease in the phosphorylation of the regulatory serine 
(Fig. 5A,B). In PTPBR7 expressing cells, however, the 
PTPBR7 KIM-domain seems maximally phosphorylated 
under all conditions tested (Fig. 5C, D), which may 
explain the negative findings regarding ERK1/2 activity 
modulation by this receptor-type PTPRR isoform.
To determine whether the phosphatase activity and/or 
MAPK binding potential of PTPPBSy is required for the 
observed attenuation of the EGF-stimulated transient ERK 
activity (Fig. 4), PC12 cell pools were generated that stably 
express specific PTPPBSy mutants. PTPPBSy C343S and 
D309A mutants represent catalytically impaired versions 
that still may bind phosphotyrosine-containing substrates 
[25]. In the AKIM mutant the KIM-domain has been 
deleted, making it unable to associate with MAPKs [6]. 
Furthermore, because phosphorylation is known to regu­
late its association with MAPKs [9,13], we also included 
the PTPPBSy S94A/T116A double mutant in this series of 
experiments. The PTPPBSy mutant-expressing cell pools 
demonstrated expression levels that were comparable 
with or even exceeding that of wild-type PTPPBSy express­
ing cells (Fig. 6A). Again, relative phospho-ERK1/2 levels 
were determined by phospho-immunoblot analyses. 
Only in PC12 cells expressing wild type PTPPBSy or PKA- 
insensitive PTPPBSy S94A/T116A a significant decrease in 
ERK1/2 activity at 5 min, but not at 2 min, following EGF 
stimulation is apparent (Fig. 6B; p < 0.05). The catalyti- 
cally impaired mutants as well as the version without the 
KIM-domain have lost this ability, demonstrating the 
requirement of a direct association with and subsequent 
dephosphorylation of the MAPK by the PTP.
Discussion
The neuroendocrine PC12 cell line represents a paradigm 
model system to study spatial and temporal aspects of 
growth factor-induced MAPK signaling [2,26]. In this 
study we made an inventory of the MAPK-associating, 
phosphotyrosine-specific PTPs that are endogenously 
expressed in this cell system and tested their physiological 
relevance for the spatio-temporal control of EGF- and 
NGF-induced ERK1/2 activity. The PTPRR isoform 
PCPTP1 was the only detectable KIM-domain containing 
classic PTP in these cells. Knockdown of PCPTP1 protein 
levels or additional expression of its mouse ortholog 
PTPBR7, however, left transient and sustained ERK1/2 sig­
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Figure5
Assessm ent o f PTPRR KIM  dom ain  phosphorylation. A) Lysates of PTPPBSy expressing cells after overnight serum star­
vation (t = 0) and subsequent treatment with EGF, NGF or forskolin were subjected to  immunoprecipitation with monoclonal 
antibody 6A6, and captured proteins were analyzed on blot using a phospho-PKA substrate antibody (upper panel) and 6A6 
(lower panel). It was ascertained that the phospho-PKA substrate antibody remained unreactive towards PTPPBSy mutant 
S94A (data not shown). B) Quantitative representation of phospho-PTPPBSy levels determined as in A. Results, expressed as 
the ratio of the signals obtained with the phospho-PKA substrate antibody and the PTPRR antibody, are presented as mean val­
ues ± SEM (n = 3, Student's t-test, *p < 0.02). C) Representative image of PTPBR7 proteins, immunoprecipitated with antibody 
6A6 from PTPBR7 expressing cells that received the indicated stimuli, as detected with phospho-PKA substrate antibody 
(upper panel) or 6A6 (lower panel). D) Quantitative representation of phospho-PTPBR7 levels as determined in C. Results are 
presented as mean values ± SEM (n = 3).
naling in response to EGF or NGF, respectively, unaltered. 
Our finding that in this cell system PTPBR7 was constitu­
tively phosphorylated on a regulatory serine residue 
within the KIM-domain, precluding its binding to ERK, 
provides a likely explanation. Ectopic expression of the 
cytosolic PTPPBSy isoforms resulted in a decrease of EGF- 
induced, but not NGF-induced, ERK1/2 activation. This 
effect required PTPPBSy enzymatic activity and an intact 
KIM-domain, pointing to a direct association with and 
dephosphorylation of the MAPK. In line with this, only 
some 30-50% of the PTPPBSy molecules was found to be 
phosphorylated on their KIM serine residue, leaving the 
majority available for engagement in ERK binding and 
dephosphorylation.
It is unclear what causes the differential effect by the 
PTPPBSy isoforms as compared to the receptor-type 
PTPBR7 protein on the amplitude of the transient ERK
activity following EGF administration. It may well be 
attributable to the distinct subcellular localizations of 
these PTPRR isoforms or rather could reflect the much 
higher expression levels for PTPPBSy-42/PTPPBSy-37 as 
compared to PTPBR7. Why PTPPBSy ectopic expression 
affects only the transient and not the sustained ERK activ­
ity profile, however, must have other grounds. Current 
models incorporate an NGF-induced PKA-mediated sign­
aling pathway in PC12 cells [22] and, reasoning along 
these lines, PTPPBSy proteins may thus become hyper- 
phosphorylated in the KIM-domain upon NGF addition. 
In contrast, we found that treatment with EGF and NGF 
both resulted in significantly lower PTPPBSy phosphor­
ylation levels. This may be explained by assuming that the 
initial boost of ERK1/2 activity following growth factor 
addition results in a rapid KIM region-mediated associa­
tion of PTPPBSy and ERK1/2, thereby protecting the regu­
latory serine in the KIM region from subsequent
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2 5
Time of EGF stimulus (min.)
Figure6
W ild  type and non-phosphorylatable PTPPBSy affect 
ERK activity. A) Expression analysis of wild type and 
mutant PTPPBSy proteins. Equal amounts of protein from 
PC12 cells stably expressing wild type (WT) or mutant 
(AKIM, D309A, S94A/T114A, and C343S) PTPPBSy were 
subjected to SDS-PAGE and immunoblot analysis using anti­
body 6A6. B) EGF-induced ERK1/2 activity in PC12 cells sta­
bly expressing PTPPBSy protein variants. Serum starved cells 
that stably express PTPPBSy mutants were stimulated with 
10 ng/ml EGF for 2 or 5 min, and lysed. Relative phospho- 
ERK1/2 levels were determined via immunoblot analysis as 
described in the legends to Fig. 2. Results are presented as 
mean values ±  SEM (n = 4, Student's t-test; *p < 0.05).
phosphorylation. Irrespective, the PKA-mediated signal­
ing that results from NGF treatment of PC12 cells, and 
that is required for the sustained nature of the ERK activity 
as compared to the transient EGF effects [22], does not 
explain the PTPPBSy selective effect.
In line with our findings, ectopic overexpression of a 
cytosolic version of PTP-SL (thus resembling PTPPBSy iso­
forms) in PC12 cells has been reported previously to 
result in reduced phospho-ERK5 and phospho-ERK1/2 
levels following EGF administration [27]. Those data, 
however, were not quantified nor tested for statistical sig­
nificance. In contrast with our studies, Ogata and cowork­
ers did observe a suppressive effect of PTPBR7 on 
sustained ERK activity in PC12 cells [19]. Those experi­
ments, however, involved transient transfections that 
likely result in much higher PTPBR7 expression levels, and 
activation of the PC12 cells was done through co-transfec­
tion of constitutively active MEK1 instead of NGF admin­
istration. Furthermore, not ERK phosphorylation status 
but transcriptional activity of its downstream substrate 
Elk1 was used as a read-out, and together this may have 
caused an exaggeration of effects.
PCPTP1, the rat homologue of mouse PTPBR7, is abun­
dantly expressed in several rat brain regions, including the 
cerebellum, cerebral cortex and the hippocampus [17]. 
Intriguingly, PCPTP1 mRNA levels are increased 9-fold 
over the initial 8 h of NGF-induced differentiation of 
PC12 cells [14], in line with a role in neuronal differenti­
ation induced by sustained ERK activity. Our protein 
knockdown experiment, however, are at odds with a criti­
cal role for PCPTP1 in ERK1/2-dependent processes in 
PC12 cells. Other KIM-domain-containing tyrosine-spe­
cific PTPs cannot camouflage the impact of PCPTP1 sign­
aling since we excluded expression of other PTPRR 
isoforms, STEP and HePTP/LC-PTP in PC12 cells. On the 
other hand, redundancy with KIM- domain-containing 
dual-specificity phosphatases (MKP/DUSP) may well 
explain PTPRR's modest effect on ERK1/2 signaling. In 
Drosophila, for example, redundancy regarding ERK inacti­
vation was encountered for DMKP3, a homolog of mam­
malian MKP-3/MKP-4, and PTP-ER, the Drosophila 
homolog of PTPRR [28]. Potential candidates that could 
take over the role of the PTPRR proteins in PC12 cells are 
MKP-3, MKP-4, MKP-X and Dusp2, in view of their local­
ization in the cytoplasm and high specificity towards 
ERK1/2 [5]. We detected MKP-3 and MKP-X transcripts in 
PC12 cells by RT-PCR analyses (data not shown) but did 
not observe alterations in growth factor-induced ERK1/2 
activity profiles following RNA interference strategies 
towards depletion of MKP-3 and MKP-X (data not 
shown). It should be noted that verification of changes in 
MKP protein levels was not performed due to lack of suit­
able antibodies.
What other substrate targets for PCPTP1 may exist in 
PC12 cells to explain its endogenous presence? Besides 
ERK1/2, PTPRR proteins were shown to bind the MAPK 
family members p38a and ERK5 [6,9,13,27,29] but these 
studies were mostly performed in non-neuronal cells, 
using either recombinant proteins or ectopically 
expressed phosphatases and MAPKs. Further studies 
towards the identification of the physiological targets of 
PTPRR isoforms are therefore needed. In addition, current 
in vitro studies might be hampered by the fact that poten­
tial ligands for the PCPTP1/PTPBR7 extracellular part, 
which may critically control the activity of the phos­
phatase, have not been identified yet. Also in view of the 
restricted expression pattern of the Ptprr gene [17,24,30] 
and its conserved potency to generate multiple protein 
isoforms through the use of different promoters, alterna­
tive splicing and multiple start codons [18,20,30] it may
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well be that the tyrosine phosphatase PTPRR family mem­
bers will prove physiological regulators of MAPK signal­
ing in other cell systems and following different stimuli 
than the ones tested here. Given the lack of endogenous 
PTPRR expression in many neuronal cell lines, studies in 
PTPRR deficient mice are eagerly awaited to address their 
functional significance in MAPK signaling in vivo.
Conclusion
The PTPRR isoform PCPTP1 is the sole tyrosine-specific 
PTP in PC12 cells that is able to bind ERK MAPKs through 
its KIM-domain and it is readily up-regulated upon 
growth factor-induced differentiation of these cells. Still, 
the physiological regulation of ERK1/2 signaling in PC12 
cells could not be ascribed to this PTP. We conclude that 
other, dual-specificity MAPK phosphatases may act as 
major regulators of EGF- and NGF-induced signaling 
pathways in these cells.
Methods
RT-PCR
Total RNA from exponentially growing PC12 cells, rat cer­
ebellum, mouse cerebrum or spleen was purified using 
RNazol B (Campro Scientific, Veenendaal, The Nether­
lands). RT-PCR analyses were performed essentially as 
described [31]. Briefly, cDNA was synthesized from total 
RNA by random hexamer priming using SuperScript™ II 
RNase H- Reverse Transcriptase (Invitrogen Life Technolo­
gies, Breda, The Netherlands) and used for PCR. Ampli­
fied products were analyzed on agarose gels. Primers used 
are: PCPTP1-forward 5 '-CCTCAATGCACACACTAT- 
GAGG-3'; PCPTP1-Ce-forward 5'-CTTCAGCTCGCAGGC 
TTTC-3'; PTPPBSy (rat)-forward 5 '-GTGCAGGACGT- 
GGAGGAAG-3'; PTPRR-reverse 5'-TCCTTCTTTGCTCCA- 
GAT-3'; STEP-forward 5'-GAGGACTACCGGCTGCGAC- 
3'; STEP-reverse 5'-GGCTCATGGCGTGGTGCAC-3'; 
HePTP-forward 5 '-CATCTGCTCAGT GAACACACC-3'; 
HePTP-reverse 5'-GTCTGCTACAGTGTTGGGC-3'; P- 
actin-forward 5'-GCTAGAGCTGCCTGACGG-3' and P- 
actin-reverse 5'-GAGGCCAGGATGGAGCC-3'.
Plasmids
Subcloning of a XhoI-NotI fragment from pIRES2-eGFP 
(Clontech) into XhoI-NotI digested retroviral plasmid 
pLXSN (Clontech) generated pLXSN-IRES2-eGFP. The 
BamHIsite in pLXSN-IRES2-eGFP was subsequently used 
to insert the BglII insert from pSG5-PTPPBSy-FL [20], ren­
dering pLXSN-PTPPBSy-IRES2-eGFP. By inserting the N- 
terminus-encoding EcoRI fragment from PTPBR7-eGFP
[23] into EcoRI-digested pLXSN-PTPPBSy-IRES2-eGFP we 
generated pLXSN-PTPBR7-IRES2-eGFP. Mutant pLXSN- 
PTPPBSy constructs were generated as follows. First 
mutant PTP-SL open reading frames were excised from 
pRK5-PTP-SL expression vectors ([6] kindly provided by 
dr. R. Pulido, Valencia, Spain) using NotI and XhoI, and
ligated in between the corresponding sites in pLXSN. 
Using BstBI we subsequently excised the mutation-con­
taining sequence parts from the obtained plasmids and 
inserted them into BstBI-digested pLXSN-PTPPBSy-IRES2- 
eGFP. For siRNA constructs, appropriate oligonucleotides 
were annealed and ligated in the pSUPER-Retro vector 
pSR [21]. Plasmids pSR-1211 and pSR-2380 encode siR- 
NAs that target the nucleotides 1211-1229 and 2380­
2398 in the PCPTP1 mRNA [Genbank:D38292], respec­
tively. All constructs were verified by sequence analysis.
Cell culture and retroviral transduction
PC12 cells (ATCC #CRL-1721) were grown on collagen- 
coated dishes in DMEM supplemented with 10% FCS and 
5% horse serum (HS) at 37°C. Ecotropic Phoenix packag­
ing cells [32] were cultured in DMEM, 10% FCS. For ret­
rovirus production, Phoenix cells were transiently 
transfected by calciumphosphate precipitation. Twenty- 
four hours after transfection, medium was replaced by 
DMEM containing 10% FCS and 5% HS. After 10 h retro­
virus-containing medium was collected, filtered through a
0.45-^m pore-size filter and supplemented with poly- 
brene (Sigma-Aldrich Chemie B.V., Zwijndrecht, The 
Netherlands) to a final concentration of 5 |ig/ml. PC12 
cells were infected by replacing culture medium with 
undiluted polybrene- and retrovirus-containing medium 
for 8-16 h. After four subsequent rounds of infection, 
transduced cells were selected for 2-3 weeks in medium 
containing 500 |ig/ml G418 (Gibco Europe, Breda, The 
Netherlands) or 2.5 |ig/ml puromycin (Sigma-Aldrich 
Chemie B.V.), respectively.
Immunoblot analysis
Cells were seeded in six-well plates at a density of 1*106 
cells/well. The next day medium was replaced by DMEM 
without serum. After o/n serum deprivation, cells were 
treated with 0.075-100 ng/ml EGF (a kind gift of Dr. J. 
van Zoelen, Nijmegen, The Netherlands) or 50 ng/ml 
NGF (N6009, Sigma-Aldrich Chemie B.V.) for different 
time periods. Cells were washed twice with ice-cold phos­
phate-buffered saline (PBS) before being scraped with a 
rubber policeman in 75|il lysis buffer: 50 mM Tris-HCl, 
pH 7.5; 150 mM NaCl; 1% triton X-100; 100 mM NaF; 2 
mM Na3VO4; 20 mM Na4P2O7; 1 mM PMSF; protease 
inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, 
Germany). Lysis was continued on ice for 30 min and 
insoluble components were subsequently pelleted by cen­
trifugation for 25 min at 14.000 rpm and 4°C. Superna- 
tants were stored at -20 °C until further use. Protein 
concentrations were determined spectrophotometrically 
[33].
Protein samples (8 |ig) were subjected to SDS-PAGE on 
10% PA gels and blotted onto polyvinylidene fluoride 
(PVDF) membranes. Blots were blocked for 30 min using
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3% non-fat dry milk in TBS-T (10 mM Tris-HCl, pH 8.0; 
150 mM NaCl; 0.05% Tween-20) and incubated over­
night at 4°C with a 1:2000 dilution of a phospho-ERK1/2 
monoclonal antibody (#9106, Cell Signaling Technology, 
Beverly, USA). Following three washes with TBS-T, blots 
were incubated for 1 h with a 1:10,000 dilution of perox­
idase-conjugated goat anti-mouse IgG (Pierce Biotechnol­
ogy Inc., Rockford, IL, USA) in 3% non-fat dry milk in 
TBS-T. Immunoreactive bands were detected with Lumi- 
LightPLUS Western Blotting Substrate (Roche Diagnostics 
GmbH) using a BioChemi imaging system and obtained 
signals were quantified with the Labworks 4.0 program 
(UVP BioImaging Systems, Cambridge, UK). Blots were 
then stripped for 40 min at 60°C (in 62.5 mM Tris-HCl, 
pH 6.6; 100 mM P-mercapto-ethanol; 2% SDS), washed 
with TBS-T and reprobed for 1 h with rabbit polyclonal 
ERK1 (C-16) antibody (sc-93, Santa Cruz Biotechnology, 
Inc., Santa Cruz, USA) at a dilution of 1:8000 in TBS-T 
containing 3% non-fat dry milk. Peroxidase-conjugated 
goat anti-rabbit IgG (Pierce Biotechnology Inc.) was used 
for detection and quantitation as described above. Ratios 
of the phospho-ERK1/2/total ERK1 signals were deter­
mined for every sample and, to be able to compare signal 
ratios originating from different blots, a reference stand­
ard sample (corresponding to a PC12 cell lysate following 
5 min treatment with EGF) was included on each blot.
PTPRR expression levels were determined by subjecting 
50 |ig of total protein to SDS-PAGE and immunoblot 
analysis as described above, using monoclonal antibody 
6A6 [20]. Phospho-PTPPBSy and phospho-PTPBR7 levels 
were determined by western blotting of 6A6 immunopre- 
cipitates, performed as described previously [20], from 
PTPPBSy or PTPBR7 expressing cells which had been incu­
bated with 10 ng/ml EGF, 50 ng/ml NGF or 10 |iM forsko- 
lin after overnight serum starvation. Blots were incubated 
simultaneously with a rabbit monoclonal phospho-PKA 
substrate (RRXS*/T*)(100G7) antibody (#9624, Cell Sig­
naling Technology) and with 6A6, both in a 1:1000 dilu­
tion. Goat anti-mouse and goat anti-rabbit secondary 
antibodies conjugated to Alexa Fluor 680 (Molecular 
Probes) or IRDye800 (Rockland Immunochemicals) fluo­
rescent dyes were used for detection and quantification on 
an Odyssey infrared imaging system (LI-COR).
Immunofluorescence microscopy
Cells, cultured on collagen-coated coverslips, were fixed at 
room temperature for 30 min in PHEM buffer (60 mM 
PIPES; 25 mM HEPES, pH 6.9; 10 mM EGTA; 2 mM 
MgCl2) containing 4% paraformaldehyde, and subse­
quently washed with PBS and permeabilized for 5 min 
using 0.2% Triton X-100 in PBS. Aspecific sites were 
blocked by incubating for 30 min with 4% BSA in PBS 
before cells were incubated for 1 h with a 1:500 dilution 
of rabbit polyclonal a-SL antiserum [24] in PBS contain­
ing 0.4% BSA. Following three washes with PBS, cells were 
incubated for 1 h in a 1:300 dilution of Alexa568-conju- 
gated goat-anti-rabbit IgG (Molecular Probes) in PBS,
0 .4 .  BSA. Following PBS washes and methanol dehydra­
tion, coverslips were mounted on glass slides using 
Mowiol (Sigma-Aldrich), and images were collected using 
confocal laser scanning microscopy (MRC1024, Bio-rad).
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